Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Hydralazine As a Selective Probe Inactivator of Aldehyde Oxidase in Human Hepatocytes: Estimation of the Contribution of Aldehyde Oxidase to Metabolic Clearance

Timothy J. Strelevitz, Christine C. Orozco and R. Scott Obach
Drug Metabolism and Disposition July 2012, 40 (7) 1441-1448; DOI: https://doi.org/10.1124/dmd.112.045195
Timothy J. Strelevitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine C. Orozco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Scott Obach
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 40 no. 7 1441-1448
DOI 
https://doi.org/10.1124/dmd.112.045195
PubMed 
22522748

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received February 22, 2012
  • Accepted April 20, 2012
  • Published online June 20, 2012.

Article Versions

  • Earlier version (April 20, 2012 - 08:42).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Timothy J. Strelevitz,
  2. Christine C. Orozco and
  3. R. Scott Obach
  1. Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut
  1. Address correspondence to:
    Timothy Strelevitz, Pfizer Inc., Eastern Pont Rd., Groton, CT 06340. E-mail: timothy.j.strelevitz{at}pfizer.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: April 2012 to January 2021

AbstractFullPdf
Apr 20124350118
May 2012260093
Jun 201237015125
Jul 201232628109
Aug 20121641753
Sep 2012114927
Oct 2012961736
Nov 20121131329
Dec 20121141325
Jan 20131031230
Feb 2013601628
Mar 201371721
Apr 2013591022
May 2013871233
Jun 201344915
Jul 2013581841
Aug 2013401218
Sep 2013842637
Oct 2013432830
Nov 2013422026
Dec 2013321317
Jan 2014372019
Feb 2014232018
Mar 2014393120
Apr 2014241414
May 2014282025
Jun 2014213325
Jul 2014262413
Aug 2014281814
Sep 2014233634
Oct 2014452124
Nov 2014271317
Dec 2014342319
Jan 2015382727
Feb 2015202429
Mar 2015282535
Apr 2015172011
May 2015251717
Jun 2015202416
Jul 2015292626
Aug 2015351519
Sep 2015361911
Oct 2015221214
Nov 2015212118
Dec 201561717
Jan 2016202721
Feb 2016171425
Mar 2016162636
Apr 2016102027
May 2016182112
Jun 2016201828
Jul 2016271034
Aug 2016292828
Sep 201691512
Oct 201633339
Nov 201643525
Dec 201611613
Jan 201734819
Feb 201713616
Mar 201756211
Apr 201732817
May 201792823
Jun 201761920
Jul 201782210
Aug 201712319
Sep 201715528
Oct 201704935
Nov 201745831
Dec 20170239
Jan 20181279
Feb 20180369
Mar 201802211
Apr 201815116
May 201824220
Jun 201832911
Jul 201882117
Aug 201833223
Sep 201813128
Oct 201832616
Nov 201854827
Dec 2018332317
Jan 201919910
Feb 20191967
Mar 20192587
Apr 20192439
May 201919811
Jun 2019111221
Jul 201923136
Aug 2019281111
Sep 201932911
Oct 2019182211
Nov 20192948
Dec 20193869
Jan 202047135
Feb 20201366
Mar 202033124
Apr 2020531011
May 2020251511
Jun 20202344
Jul 20202489
Aug 20201176
Sep 202024119
Oct 20202896
Nov 20201096
Dec 20201385
Jan 202116157

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 40 (7)
Drug Metabolism and Disposition
Vol. 40, Issue 7
1 Jul 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Hydralazine As a Selective Probe Inactivator of Aldehyde Oxidase in Human Hepatocytes: Estimation of the Contribution of Aldehyde Oxidase to Metabolic Clearance
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

HYDRALAZINE AS A SELECTIVE AO INHIBITOR IN HEPATOCYTES

Timothy J. Strelevitz, Christine C. Orozco and R. Scott Obach
Drug Metabolism and Disposition July 1, 2012, 40 (7) 1441-1448; DOI: https://doi.org/10.1124/dmd.112.045195

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

HYDRALAZINE AS A SELECTIVE AO INHIBITOR IN HEPATOCYTES

Timothy J. Strelevitz, Christine C. Orozco and R. Scott Obach
Drug Metabolism and Disposition July 1, 2012, 40 (7) 1441-1448; DOI: https://doi.org/10.1124/dmd.112.045195
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Candesartan glucuronide serves as a CYP2C8 inhibitor
  • Role of AADAC on eslicarbazepine acetate hydrolysis
  • Gene expression profile of human intestinal epithelial cells
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics